Extensive Clonal Branching Shapes the Evolutionary History of High-Risk Pediatric Cancers
- 1 April 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (7), 1512-1523
- https://doi.org/10.1158/0008-5472.can-19-3468
Abstract
Darwinian evolution of tumor cells remains underexplored in childhood cancer. We here reconstruct the evolutionary histories of 56 pediatric primary tumors, including 24 neuroblastomas, 24 Wilms tumors and 8 rhabdomyosarcomas. Whole genome copy number and whole exome mutational profiling of multiple regions per tumor was performed followed by clonal deconvolution to reconstruct a phylogenetic tree for each tumor. Overall, 88% of the tumors exhibited genetic variation among primary tumor regions. This variability typically emerged through collateral phylogenetic branching, leading to spatial variability in the distribution of more than 50% (96/173) of detected diagnostically informative genetic aberrations. Single cell sequencing of 547 individual cancer cells from eight solid pediatric tumors confirmed branching evolution to be a fundamental underlying principle of genetic variation in all cases. Strikingly, cell-to-cell genetic diversity was almost twice as high in aggressive compared to clinically favorable tumors (median Simpson index of diversity 0.45 vs. 0.88; p=0.029). Similarly, a comparison of multiregional sampling data from a total of 274 tumor regions showed that new phylogenetic branches emerge at a higher frequency per sample and carry a higher mutational load in high-risk than in low-risk tumors. Timelines based on spatial genetic variation showed that the mutations most influencing relapse risk occur at initiation of clonal expansion in neuroblastoma and rhabdomyosarcoma, while in Wilms tumor they are late events. Thus, from an evolutionary standpoint, some high-risk childhood cancers are born bad, while others grow worse over time.Other Versions
Funding Information
- Swedish Research Council (2016-01022)
- Swedish Cancer Society (CAN2015/284)
- Swedish Childhood Cancer Foundation (PR2016-024, NCP2015-0035)
This publication has 51 references indexed in Scilit:
- PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group reportPediatric Blood & Cancer, 2013
- Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogeneFNDC3BCell Cycle, 2012
- Molecular profiling reveals frequent gain of MYCN and anaplasia‐specific loss of 4q and 14q in wilms tumorGenes, Chromosomes and Cancer, 2011
- Analysis of Wilms Tumors Using SNP Mapping Array-Based Comparative Genomic HybridizationPLOS ONE, 2011
- Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneityGenome Biology, 2011
- Identification of PAX3‐FKHR‐regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: Focus on MYCN as a biologically relevant targetGenes, Chromosomes and Cancer, 2008
- Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arraysGenome Biology, 2008
- The Role of MYCN in the Failure of MYCN Amplified Neuroblastoma Cell Lines to G1 Arrest After DNA DamageCell Cycle, 2006
- Gain of Chromosome Arm 17q and Adverse Outcome in Patients with NeuroblastomaThe New England Journal of Medicine, 1999
- Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease StageScience, 1984